Eden Biodesign restructures its executive management team
Dr Derek Ellison appointed Chief Operating Officer as business operations expand
Eden Biodesign announced a management restructure to include the appointment of Dr Derek Ellison as Chief Operating Officer (COO). The restructure results in changes in responsibility for seven executive and senior management members, to support growing demand as Eden continues to expand globally.
Newly appointed COO, Dr Derek Ellison (Co-Founder of Eden and previously VP Development and Manufacturing) has taken the position at a time when Eden Biodesign branches further into the US.
Dr Anita Bate, (Co-Founder of Eden) will take up the role of Chief Scientific Officer from Science Director. Anita’s responsibilities will include managing a dedicated transatlantic team of people tasked with looking at new opportunities for Eden, exploring and evaluating new technologies.
Team restructures are also taking place globally, as Dr Phil Ball moves from the UK over to the US offices. Phil will take up the role of Technical Director from Analytical and Purification Development Manager, allowing Phil to support Roger Lias, President of Eden Biodesign, Inc. (the US subsidiary of Eden), as US business continues to expand.
The management team has been further strengthened, resulting in promotion and changes in responsibility for four members of staff. Dr David Simpson moves to become Process Development Manager, Dr Mandy Shipman takes up the role of Biopharm Development Consultant, Gina Wenham takes on responsibility for the Analytical Development team alongside Quality Control and Alison Justice has been promoted to QA Director.
Other news from the department people
